Inside Cytolin - Humanity's Answer to AIDS

In response to new economic and regulatory realities, CytoDyn, Inc. (Pink Sheet: CYDY) has made a sea change in its strategy for developing Cytolin®, the Company’s unique immune therapy for treating HIV/AIDS. Studies of the drug will be designed and conducted by Massachusetts General Hospital, one of the premier teaching hospitals in Boston, Massachusetts, as part of its mission to advance medical knowledge and treatments through research, education and patient care.

During the past decade, significant improvements in the antiviral “cocktails” used to treat HIV/AIDS have saved countless lives and is well tolerated by most patients, although all drugs have side effects. These drugs also require a withholding time of about five years from initial infection. It is due to the fact that drugs that are being used in start off stage result in the virus getting more resistant, and rendering them ineffective.

Cytolin® is the brainchild of scientist Allen D. Allen, the CEO of CytoDyn, which has been developing Cytolin® as its lead product since the Company’s inception in 2003.Cytolin®, instead of being an antiretroviral drug, it is a monoclonal antibody administered by intravenous infusion. It is designed to prevent the wholesale destruction of helpful CD4 T cells by a person’s own killer T cells, without interfering in the virus life-cycle. It means that healthcare providers could treat individuals infected with HIV more quickly, rather than just spending years watching and waiting.

The company in collaboration with the Massachusetts General Hospital will conduct a six month ex-vivo study of Cytolin.    This study would be then followed by an in-vivo study which will sharpen the role of Cytolin in maintaining a suitable amount of CD4 cells. Eric S. Rosenberg, MD, the principal investigator and an Associate Professor of Medicine in the Infectious Diseases Division of Massachusetts General Hospital, made the initial protocol of the study which was supported by a comprehensive due diligence report prepared by David Scondras, a Boston-based AIDS activist.

CytoDyn’s management believes that the results are unlikely to be surprising and unexpected, because it has been already used to treat hundreds of patients over extended period of time.     But still the study will validate its positive outcomes, and Massachusetts General Hospital is free to publish any study results that are conducted there.

Conclusion – how to you suggest that this step towards drug development would provide a better solution to the AIDS epidemic? Unlike other companies, which mainly focus of just the efficacy-testing of drug, what would CytoDyn achieve from getting their product independently tested? Please share your views and ideas.

Take Care

SH